FIG. 1.

Percentages of Leishmania-reactive CD4⁺ and CD8⁺ proliferating T cells in patients with CL (top panel) or ML (bottom panel) during the active disease, at end-T, at 6m-T, and 1 to 17 years after the end of therapy (long-term). Results are expressed as means ± standard errors of the means. Averages of the CD4⁺/CD8⁺ ratio are also represented.